Upon combination with vinorelbine, multiple immunologic synergies may have supported therapeutic efficacy: (1) IL-15 may have counteracted chemotherapy-induced lymphodepletion, preserving immune function [6]; (2) tumor cell injury from chemotherapy may have increased susceptibility to NK-mediated cytotoxicity, amplified by IL-12/IL-15 activation [7]; and (3) the combination may have promoted immunogenic cell death, tumor antigen release, and favorable toxicity profiles via complementary mechanisms [18,19,20]. This evidence concerns the gene IL15 and neoplasm.